0
No votes yet
Online Exclusive Article

Carfilzomib: A Next-Generation Proteasome Inhibitor for Multiple Myeloma Treatment

Elizabeth Bilotti
CJON 2013, 17(2), E35-E44 DOI: 10.1188/13.CJON.E35-E44

Although the incidence of multiple myeloma (MM) is increasing, the median overall survival and the number of agents in the pipeline for treating MM also are increasing. Response rates higher than 80% are not uncommon in the frontline setting when the novel agents thalidomide, lenalidomide, and bortezomib are used in combination. Response rates and survival also have improved in disease that has relapsed after treatment with conventional therapies. The focus of research has now shifted to improving survival and disease response in patients refractory to current treatment paradigms. New agents are targeting new pathways, as well as existing mechanisms known to be effective, but with different safety profiles. Carfilzomib is a potent, selective, irreversible inhibitor of the ubiquitin-proteasome pathway. The drug is a next-generation proteasome inhibitor found to be safe and effective for patients with relapsed and refractory MM, where treatment options are limited. As with any newly approved agent, one should recognize that drugs within the same class will be administered differently and often cause dissimilar treatment-related toxicities. Oncology nurses are crucial to the successful administration of chemotherapeutic agents such as carfilzomib, and an understanding of management techniques is paramount to quality patient care.

References 

Alsina, M., Trudel, S., Furman, R. R., Rosen, P. J., O'Connor, O. A., Comenzo, R. L., … Goy, A. (2012). A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. <i>Clinical Cancer Research, 18</i>, 4830-4840.

Badros, A. Z., Vij, R., Martin, T., Zonder, J. A., Kunkel, L., Wang, Z., … Niesvizky, R. (2013). Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. <i>Leukemia.</i> Advance online publication. doi:10.1038/leu.2013.29

Baird-Powell, S. (2006). Hyponatremia/hypernatremia. In D. Camp-Sorrell & R. Hawkins (Eds.), <i>Clinical manual for the oncology advanced practice nurse</i> (2nd ed., pp. 1049-1057). Pittsburgh, PA: Oncology Nursing Society.

Bilotti, E., Gleason, C. L., & McNeill, A. (2011). Routine health maintenance in patients living with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. <i>Clinical Journal of Oncology Nursing, 15</i>(Suppl. 1), S25-S40. doi:10.1188/11.S1.CJON.25-40

Bisanz, A. K., Woolery, M. J., & Eaton, L. H. (2009). Constipation. In L. H. Eaton & J. M. Tipton (Eds.), <i>Putting evidence into practice: Improving oncology patient outcomes</i> (pp. 85-90). Pittsburgh, PA: Oncology Nursing Society.

ClinicalTrials.gov. (2013). Phase 3 study with carfilzomib and dexamethasone versus velcade and dexamethasone for relapsed multiple myeloma patients (ENDEAVOR). Retrieved from <a target="_blank" href='http://www.clinicaltrials.gov/ct2/show/NCT01568866?term=NCT01568866&rank...

Damron, B. I., Samsonow, S. M., & Belansky, H. (2009). Prevention of bleeding. In L. H. Eaton & J. M. Tipton, J. M. (Eds.), <i>Putting Evidence Into Practice: Improving oncology patient outcomes</i> (pp. 253-255). Pittsburgh, PA: Oncology Nursing Society.

Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., … Bennett, M. K. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. <i>Cancer Research, 67</i>, 6383-6391.

Dimopoulos, M. A., Terpos, E., Chanan-Khan, A., Leung, N., Ludwig, H., Jagannath, S., … San Miguel, J. (2010). Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology, 28</i>, 4976-4984. doi:10.1200/JCO.2010.30.8791

DiSalvo, W. M., Joyce, M. M., & Belansky, H. (2009). Dyspnea. In L. H. Eaton & J. M. Tipton (Eds.), <i>Putting evidence into practice: Improving oncology patient outcomes</i> (pp. 135-138). Pittsburgh, PA: Oncology Nursing Society.

Faiman, B. M., Mangan, P., Spong, J., Tariman, J. D., & the International Myeloma Foundation Nurse Leadership Board. (2011). Renal complications in multiple myeloma and related disorders: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. <i>Clinical Journal of Oncology Nursing, 15</i>(Suppl. 1), S66-S76. doi:10.1188/11.CJON.S1.66-76

Hájek, R., Bryce, R., Ro, S., Klencke, B., & Ludwig, H. (2012). Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). <i>BMC Cancer, 12</i>, 415. doi:10.1186/1471-2407-12-415

Harvey, D., Lonial, S., Patel, P., McCulloch, L., Niesvizky, R., & Kaufman, J. (2012). Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [Abstract 0844]. <i>Haematologica, 97</i>(Suppl. 2), 346.

Jagannath, S., Vij, R., Stewart, A. K., Trudel, S., Jakubowiak, A. J., Reiman, T., … Siegel, D. S. (2012). An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma, and Leukemia, 12</i>, 310-318. doi:10.1016/j.clml.2012.08.003

Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., … Vij, R. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood, 120</i>, 180-189. doi:10.1182/blood-2012-04-422683

Kennedy, M. M. (2006). Pneumonia. In D. Camp-Sorrell & R. Hawkins (Eds.), <i>Clinical manual for the oncology advanced practice nurse</i> (2nd ed., pp. 195-208). Pittsburgh, PA: Oncology Nursing Society.

Kolb, B., Hulin, C., Caillot, D., Benboubker, L., Tiab, M., Blin, N., … Moreau, P. (2012). Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma [Abstract 8009]. Retrieved from <a target="_blank" href='http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c...

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., … Durie, B. G. (2012). Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study. <i>Leukemia, 26</i>, 149-157.

Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., … Gertz, M. A. (2008). Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood, 111</i>, 2516-2520.

Lonial, S., Niesvizky, R., McCulloch, L., Rajangam, K., & Vij, R. (2012). Cardiac and pulmonary safety profile of single-agent carfilzomib from four phase 2 studies in patients with relapsed and/or refractory multiple myeloma [Abstract 4037]. Retrieved from <a target="_blank" href='http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/2...

Martin, T., Vij, R., Badros, A., Patel, P., McCulloch, L., & Jagannath, S. (2012). Carfilzomib is associated with a low rate of typically mild to moderate, nondose-limiting treatment-emergent peripheral neuropathy [Abstract 0857]. <i>Haematologica, 97</i>(Suppl. 1), 352.

Miceli, T., Colson, K., Gavino, M., & Lilleby, K. (2008). Myelosuppression associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. <i>Clinical Journal of Oncology Nursing, 12</i>(Suppl. 1), 13-20. doi:10.1188/08.CJON.S1.13-19

Mikhael, J. R., Reeder, C. B., Libby, E. N., III, Costa, L. J., Bergsagel, P. L., Buadi F, … Stewart, A. K. (2012). Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma [Abstract 445]. Retrieved from <a target="_blank" href='http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/2...

Mitchell, S. A., & Beck, S. L. (2009). Fatigue. In L. H. Eaton & J. M. Tipton (Eds.), <i>Putting evidence into practice: Improving oncology patient outcomes</i> (pp. 149-153). Pittsburgh, PA: Oncology Nursing Society.

Moreau, P., Palumbo, A. P., Stewart, A. K., Rajkumar, V., Jakubowiak, A. J., Halka, K., … Siegel, D. S. (2011). A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM) [Abstract TPS225]. Retrieved from <a target="_blank" href='http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c...

Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau J. L. (2012). Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood, 120</i>, 947-959. doi:10.1182/blood-2012-05-403733

Muehlbauer, P., Thorpe, D., & Belansky, H. (2009). Diarrhea. In L. H. Eaton & J. M. Tipton (Eds.), <i>Putting evidence into practice: Improving oncology patient outcomes</i> (pp. 119-125). Pittsburgh, PA: Oncology Nursing Society.

National Cancer Institute Cancer Therapy Evaluation Program. (2010). <i>Common terminology criteria for adverse events</i> [v.4.03]. Retrieved from <a target="_blank" href='http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5...

Niesvizky, R., Martin, T. G., 3rd, Bensinger, W., Alsina, M., Siegel, D. S., Kunkel, L. A., … Wang, M. (2013). Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Clinical Cancer Research.</i> Advance online publication. doi:10.1158/1078-0432.CCR-12-3352

Nooka, A. K., Badros, A. Z., Patel, P., McCulloch, L., Lonial, S., & Kaufman, J. L. (2012). Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma [Abstract 8086]. Retrieved from <a target="_blank" href='http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c...

O'Connor, O. A., Stewart, A. K., Vallone, M., Molineaux, C. J., Kunkel, L. A., Gerecitano, J. F., & Orlowski, R. Z. (2009). A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. <i>Clinical Cancer Research, 15</i>, 7085-7091.

Onyx Pharmaceuticals Inc. (2012). <i>Kyprolis™ (carfilzomib) for injection</i> [Package insert]. San Francisco, CA: Author.

Papadopoulos, K., Lee, P., Singhal, S., Holahan, J. R., Tolcher, A. W., Patnaik, A., … Siegel, D. S. (2011). PX-171-007: A phase 1b study evaluating the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory multiple myeloma [Abstract 0898]. <i>Haematologica, 96</i>(Suppl. 2), 374.

Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., … Sonneveld, P. (2011). Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia, 26</i>, 595-608. doi:10.1038/leu.2011.346

Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., … Turner, M. B. (2012). Heart disease and stroke statistics—2012 update: A report from the American Heart Association. <i>Circulation, 125</i>, e2-e220. doi:10.1161/CIR.0b013e31823ac046

Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., … Jagannath, S. (2012). A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood, 120</i>, 2817-2825. doi:10.1182/blood-2012-05-425934

Siegel, D. S., Wang, M., Martin, T. G., Infante, J. R., Kaufman, J. L., Ranjangam, K., … Vij, R. (2012). A phase 2 study of prolonged carfilzomib therapy in patients with multiple myeloma previously enrolled in carfilzomib clinical trials [Abstract 2962]. Retrieved from <a target="_blank" href='http://ash.confex.com/ash/2012/webprogram/Paper49064.html'>http://ash.co...

Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. <i>CA: A Cancer Journal for Clinicians, 63</i>, 11-30. doi:10.3322/caac.21166

Smith, L. C., Bertolotti, P., Curran, K., & Jenkins, B. (2008). Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. <i>Clinical Journal of Oncology Nursing, 12</i>(3, Suppl.), 37-51. doi:10.1188/08.CJON.S1.37-51

Sonneveld, P., Asselbergs, E., Zweegman, S., Van der Holt, B., Kersten, M. J., Vellenga, E., … Lokhorst, H. (2012). Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate [Abstract 333]. Retrieved from <a target="_blank" href='http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/2...

Suter, P. M., Gorski, L. A., Hennessey, B., & Suter, W. N. (2012). Best practices for heart failure: A focused review. <i>Home Healthcare Nurse, 30</i>, 394-405. doi:10.1097/NHH.0b013e31825b11ab

Tariman, J. D., Love, G., McCullagh, E., & Sandifer, S. (2008). Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. <i>Clinical Journal of Oncology Nursing, 12</i>(3, Suppl.), 29-35. doi:10.1188/08.CJON.S1.29-35

Tyson, L. (2006). Dyspnea. In D. Camp-Sorrell & R. Hawkins (Eds.), <i>Clinical manual for the oncology advanced practice nurse</i> (2nd ed., pp. 153-157). Pittsburgh, PA: Oncology Nursing Society.

Vij, R., Siegel, D. S., Jagannath, S., Jakubowiak, A. J., Stewart, A. K., McDonagh, K., … Wang, M. (2012). An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. <i>British Journal of Haematology, 158</i>, 739-748.

Vij, R., Wang, M., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., … Siegel, D. S. (2012). An open-label, single-arm, phase II (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. <i>Blood, 119</i>, 5661-5670. doi:10.1182/blood-2012-03-414359